Michael S. Gordon - 25 Jul 2025 Form 4 Insider Report for ProMIS Neurosciences Inc. (PMN)

Role
10%+ Owner
Signature
/s/ Michael S. Gordon
Issuer symbol
PMN
Transactions as of
25 Jul 2025
Net transactions value
$0
Form type
4
Filing time
29 Jul 2025, 20:20:23 UTC
Previous filing
02 Jul 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
GORDON MICHAEL S 10%+ Owner C/O TROVE,, 40 BROAD STREET, 8TH FLOOR, BOSTON /s/ Michael S. Gordon 29 Jul 2025 0001034608
This filing has been restated, see here for the amended filing

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PMN Common Shares, no par value Exercise of in-the-money or at-the-money derivative security +119,800 +5.8% 2,195,429 25 Jul 2025 By Title 19 Promis F1, F2
transaction PMN Common Shares, no par value Exercise of in-the-money or at-the-money derivative security +119,800 +5.5% 2,315,229 25 Jul 2025 By Title 19 Promis F2, F3
transaction PMN Common Shares, no par value Exercise of in-the-money or at-the-money derivative security +119,800 +5.2% 2,435,029 25 Jul 2025 By Title 19 Promis F2, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PMN Tranche A Common Share Purchase Warrants Exercise of in-the-money or at-the-money derivative security $0 -119,800 -26% $0.000000 345,316 25 Jul 2025 Common Shares 119,800 See footnote F1, F2
transaction PMN Tranche B Common Share Purchase Warrants Exercise of in-the-money or at-the-money derivative security $0 -119,800 -26% $0.000000 345,316 25 Jul 2025 Common Shares 119,800 See footnote F2, F3
transaction PMN Tranche C Common Share Purchase Warrants Exercise of in-the-money or at-the-money derivative security $0 -119,800 -26% $0.000000 345,316 25 Jul 2025 Common Shares 119,800 See footnote F2, F4
transaction PMN Warrants to Purchase Common Shares Purchase +539,100 539,100 29 Jul 2025 Common Shares 539,100 See footnote F2, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On July 25, 2025, Title 19 Promis exercised 119,800 Tranche A purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 18 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 6-month data from the cohorts treated with single ascending doses of PMN310.
F2 By Title 19 Promis, a series of a Delaware limited liability company, of which the Reporting Person is the sole manager.
F3 On July 25, 2025, Title 19 Promis exercised 119,800 Tranche B purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.02 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on the earlier of (i) 30 months of the issue date and (ii) within 60 days of the public announcement via press release or the filing of a Current Report on Form 8-K of 12-month data from the cohorts treated with single ascending doses of PMN310.
F4 On July 25, 2025, Title 19 Promis exercised 119,800 Tranche C purchase warrants, each exercisable to purchase one Common Share. These warrants were exercisable at an exercise price of $2.50 per warrant share; however, following an offer by Title 19 Promis and an acceptance by the Issuer, were exercised at an exercise price of $0.83158 per share. The remainder of these warrants are currently exercisable and expire on July 31, 2029.
F5 On July 29, 2025, Title 19 Promis acquired 539,100 warrants, each exercisable to purchase one Common Share, at an exercise price of $1.25 per share. The purchase price for each warrant was $0.1875 per share. The warrants are currently exercisable and expire five years after the date of issuance.